|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein显示文摘AIM To compare the therapeutic effect andsignificances of multimodality treatment forhepatocellular carcinoma (HCC) with tumorthrombi in portal vein (PVTT).METHODS HCC patients (n = 147) with tumortrombi in the main portal vein or the first branchof portal vein were divided into four groups bythe several therapeutic methods. There wereconservative treatment group in 18 out ofpatients (group A); and hepatic artery ligation(HAL) and/or hepatic artery infusion (HAl)group in 18 patients (group B), in whompostoberative chemoembolization was doneperiodically; group of removal of HCC with PVTTin 79 (group C) and group of transcatheterhepatic arterial chemoembolization (TACE) orHAl and/or portal vein infusion (PVI) afteroperation in 32 (group D).RESULTS The median survival period was 12months in our series and the 1-, 3-, and 5-yearsurvival rates were 44.3%, 24.5% and 15.2%,respectively. The median survival times were 2,5, 12 and 16 months in group A, B, C and D,respectively. The 1-, 3- and 5-year survival rateswere 5.6%, 0% and 0% in group A; 22.2%,5.6% and 0% in group B; 53.9%, 26.9% and16.6% in group C; 79.3%, 38.9% and 26.8% ingroup D, respectively. Significant differenceappeared in the survival rates among the groups(P<0.05).CONCLUSION Hepatic resection with removalof tumor thrombi and HCC should increase thecurative effects and be encouraged for theprolongation of life span and quality of life forHCC patients with PVTT, whereas the besttherapeutic method for HCC with PVTT is withregional hepatic chemotherapy orchemoemblization after hepatic resection withremoval of tumor thrombi. | Jia Fan Zhi Quan Wu Zhao You Tang Jian Zhou Shuang Jian Qiu Zeng Chen Ma Xin Da Zhou Sheng Long Ye Liver Cancer Institute, Zhongshan Hospital, Fudan University Medical Center (Former Shanghai University), 136 Yixueyuan Road, Shanghai 200032, China | 2001 | World Journal of Gastroenterology2001，7，1： | 80 |
| 2 | Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial显示文摘BACKGROUND: Disease recurrence is a main challenge in treatment of hepatocellular carcinoma (HCC). There is no generally accepted method for preventing recurrence of HCC after resection. OBJECTIVE: To compare the efficacy of a traditional herbal medicine (THM) regimen and transarterial chemoembolization (TACE) in preventing recurrence in post-resection patients with small HCC. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a multicenter, open-label, randomized, controlled study, which was undertaken in five centers of China. A total of 379 patients who met the eligibility criteria and underwent randomization were enrolled in this trial. One hundred and eighty-eight patients were assigned to the THM group and received Cinobufacini injection and Jiedu Granule, and the other 191 patients were assigned to the TACE group and received one single course of TACE. MAIN OUTCOME MEASURES: Primary outcome measures were the annual recurrence rate and the time to recurrence. Incidence of adverse events was regarded as the secondary outcome measure. RESULTS: Among the 364 patients who were included in the intention-to-treat analysis, 67 patients of the THM group and 87 of the TACE group had recurrence, with a hazard ratio of 0.695 (P = 0.048). Median recurrence-free survival of the patients in the THM and TACE groups was 46.89 and 34.49 months, respectively. Recurrence rates at 1, 2 and 3 years were 17.7%, 33.0% and 43.5% for the THM group, and 28.8%, 42.5% and 54.0% for the TACE group, respectively (P = 0.026). Multivariate analysis indicated that the THM regimen had a big advantage for prolonging the recurrence-free survival. Adverse events were mild and abnormality of laboratory indices of the two groups were similar. CONCLUSION: In comparison with TACE therapy, the THM regimen was associated with diminished risk of recurrence of small-sized HCC after resection, with comparable adverse events. TRIAL REGISTRTION IDENTIFIER: This trial was registered in the Chinese Clinical Trial Registry with the identifier ChiCTR-TRC-07000033. | Xiao-feng Zhai Zhe Chen Bai Li Feng Shen Jia Fan Wei-ping Zhou Yun-ke Yang Jing Xu Xiao Qin Le-qun Li Chang-quan Ling | 2013 | Journal of Integrative Medicine2013，11，2： | 49 |
| 3 | 42,573 cases of hepatectomy in China: a multicenter retrospective investigation显示文摘Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma(HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients,81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein(AFP) level, and other 35% had an AFP level lower than 400 ng mL^(-1). In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was(191.7±105.6) min,the blood loss was(546.0±562.8) m L, and blood transfusion was(543.0±1,035.2) m L. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules,tumor thrombosis and high AFP level were risk factors that affect postoperative survival. | Binhao Zhang Bixiang Zhang Zhiwei Zhang Zhiyong Huang Yifa Chen Minshan Chen Ping Bie Baogang Peng Liqun Wu Zhiming Wang Bo Li Jia Fan Lunxiu Qin Ping Chen Jingfeng Liu Zhe Tang Jun Niu Xinmin Yin Deyu Li Songqing He Bin Jiang Yilei Mao Weiping Zhou Xiaoping Chen | 2018 | Science China(Life Sciences)2018，61，6： | 39 |
| 4 | Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine显示文摘Traditional Chinese medicine(TCM) is an important part of the treatment of primary liver cancer(PLC) in China; however, the current instructions for the integrative use of traditional Chinese and Western medicine for PLC are mostly based on expert opinion. There is no evidence-based guideline for clinical practice in this field. Therefore, the Shanghai Association of Chinese Integrative Medicine has established amultidisciplinary working group to develop this guideline, which focuses on the most important questions about the use of TCM during PLC treatment. This guideline was developed following the methodological process recommended by the World Health Organization Handbook for Guideline Development.Two rounds of questionnaire survey were performed to identify clinical questions; published evidence was searched; the Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the body of evidence; and recommendations were formulated by combining the quality of evidence, patient preferences and values, and other risk factors. The guideline was written based on the Reporting Items for Practice Guidelines in Healthcare tool. This guideline contains 10 recommendations related to 8 questions, including recommendations for early treatment by TCM after surgery, TCM combined with transcatheter arterial chemoembolization for advanced PLC, TCM drugs for external use, and acupuncture and moxibustion therapy. | Chang-quan Ling Jia Fan Hong-sheng Lin Feng Shen Zhen-ye Xu Li-zhu Lin Shu-kui Qin Wei-ping Zhou Xiao-feng Zhai Bai Li Qing-hui Zhou | 2018 | Journal of Integrative Medicine2018，16，4： | 38 |
| 5 | Karyotype Stability and Unbiased Fractionation in the Paleo-Allotetraploid Cucurbita Genomes显示文摘 | Honghe Sun Shan WU Guoyu Zhang Chen Jiao Shaogui Guo Yi Ren Jie Zhang Haiying Zhang Guoyi Gong Zhangcai Jia Fan Zhang Jiaxing Tian William J. Lucas Jeff J. Doyle Haizhen Li Zhangjun Fei Yong Xu | 2017 | Molecular Plant2017，10，10： | 33 |
| 6 | Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE显示文摘AIM:To evaluate the role and limitation of fast multiplanarspoiled gradient-recalled (FMPSPGR) MR dynamiccontrast scanning in the follow-up of patients with HCCtreated by transarterial chemoembolization (TACE).METHODS:Twenty-two patients with 24 HCC lesionsconfirmed by biopsy or surgical resection underwentMR imaging in 4-9wks after TACE with a superconducting1.5 T MR scanner, including SE T1WI, T2WI and FMPSPGRdynamic contrast scanning. The signal intensities of alllesions on SE T1WI, T2WI and the enhancement patternson FMPSPGR dynamic contrast scanning were observed,and the comparison was made between MRI findingsand pathological results in ail the cases.RESULTS:Of the 24 lesions, the signal intensities werevarious on SE T1WI and T2WI. On T1WI, 13 lesionsappeared as hyperintense, 4 lesions were isointenseand the other 7 lesions were hypointensese.Histologically, hyperintense lesions showed on T1WIwere viable tumor or hemorrhage; isointensities werecoagulative necrosis or inflammatory infiltration;hypointensities were tumor, liquified necrosis,coagulative necrosis or inflammatory infiltration. OnT2WI, 15 lesions appeared as hyperintense, 3 lesionswere isointense and the other 6 lesions werehypointensese. Hyperintense lesions showed on T2WIwere residuals of viable tumor, hemorrhage, liquefiednecrosis or inflammatory infiltration; isointense lesionswere residuals of viable tumor or inflammatoryinfiltration; hypointense lesions were coagulativenecrosis. On FMPSPGR dynamic contrast scanning, 18of the 24 lesions enhanced on early-phase dynamicscanning conesponding to residuals of viable tumor andthe other 6 lesions had no enhancement at this phasebecause complete necrosis were seen in the histologicexamination. On delayed-phase dynamic scanning, 6lesions had permanent enhancement appeared asinhomogeneous hyperintensity and both residuals ofviable tumor and inflammatory infiltration were foundby histologic examination. 18 lesions were hypointenseat this phase and 8 of them coexisted with peripheralring-like enhancement of the lesions resulting fromviable tumors or inflammatory infiltration.CONCLUSION: FMPSPGR MR dynamic contrast scanningcan reflect the pathologic changes of HCC treated byTACE. Especially, early-phase dynamic scanning canevaluate accurately residuals of viable tumor andnecrosis in HCC lesions. FMPSPGR dynamic contrastscanning is useful in the follow-up of patients with HCCtreated by TACE combined with SE T1WI and T2WI, butit is difficult to differentiate peripheral viable tumorsfrom inflammatory infiltration. | Fu-Hua Yan Kang-Rong Zhou Jie-Min Cheng Jian-Hua Wang Zhi-Ping Yan Reng-Rong Da Department of Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China Jia Fan Department of Hepatobiliary-surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China Yuan Ji Department of Pathology,Zhongshan Hospital,Fudan University,Shanghai 200032,China | 2002 | World Journal of Gastroenterology2002，8，4： | 32 |
| 7 | Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review显示文摘BACKGROUND: Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of sorafenib in advanced HCC patients and explore its true value for specific subgroups. DATA SOURCES: A computer-based systematic search from January 2005 to June 2011 with 'sorafenib' and 'advanced hepatocellular carcinoma' as search terms was performed for possible clinical trials. Hazard ratios (HR) and their 95% confidence intervals (CI) for overall survival (OS) and time to progression (TTP), rates of partial response (PR), rates of toxicity effects, and details of subgroup analysis were extracted. Meta-analyses were done using the software Review Manager (version 5.0). RESULTS: Six trials with 1164 patients were included. Based on three randomized controlled trials, the pooled HR (sorafenib/ placebo) was 0.66 for OS (95% CI: 0.56-0.78; P<0.00001) and 0.57 for TTP (95% CI: 0.47-0.68; P<0.00001). The pooled odds ratio (OR) for PR was 2.96 (95% CI: 0.96-9.15; P=0.06). For three single-arm trials, the pooled HR was 0.69 for OS (95% CI: 0.56-0.84; P=0.0002) and 0.64 for TTP (95% CI: 0.52-0.78; P<0.00001). The pooled OR for PR in three single-arm trials was 3.56 (95% CI: 1.22-10.39; P=0.02). Subgroup analysis indicated that sorafenib was less effective in patients with extrahepatic spread (with: P=0.13 vs without: P<0.0001), with normal alpha-fetoprotein level (AFP) (P=0.15 vs elevated: P=0.0006), and with elevated level of serum bilirubin (P=0.06 vs normal: P=0.0009). Sorafenib-based therapy significantly increased the risk of grade 3/4 hand-foot skin reaction, diarrhea, fatigue, and rash/desquamation.CONCLUSIONS: Sorafenib-based therapy benefits advanced HCC patients. Meanwhile, sorafenib is less effective for patients with extrahepatic spread, with normal AFP level and with elevated level of bilirubin. | Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，5： | 29 |
| 8 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 9 | Prevalence of Thyroid Nodules and Its Relationship with Iodine Status in Shanghai:a Population-based Study显示文摘Objective This study was designed to evaluate the prevalence of thyroid nodules(TNs) and its relationship with urine iodine concentrations(UICs) after the regional rapid economic growth and lifestyle changes. Methods A cross-sectional survey was conducted in the general population aged 15-69 years. A questionnaire regarding general and personal characteristics and relevant information was administered. Ultrasonography of the thyroid was performed, and serum triiodothyronine(T3), tetraiodothyronine(T4), serum thyroid stimulating hormone(TSH), free triiodothyronine(FT3), free tetraiodothyronine(FT4), thyroglobulin antibody(Tg Ab), thyroid peroxidase antibody(TPOAb), and TSH receptor antibody(TRAb) levels were measured for each individual subject. Results The prevalence rates of TNs in the whole population, females and males were 27.76%, 34.04%, and 21.60%, respectively. The prevalence of multiple nodules increased with age, whereas the prevalence peaks differed between males and females. The median UICs in the whole population and females with non-TNs were higher than those of subjects with TNs(P=0.0035, P=0.0068). The median UICs in subjects with a single TN were higher than those in subjects with multiple TNs(P=0.0164, P=0.0127). The result showed a U-shaped curve relationship between UIC and prevalence of TNs. The prevalence of TNs was the lowest when the UIC was 140-400 μg/L. Conclusion The prevalence of TNs was nearly 30% and increased with age. The relationship between UIC and prevalence of TNs is U-shaped, with an increase in risk when the UIC was <140 μg/L and >400 μg/L. Very low or high UIC levels need attention and correction. | SONG Jun ZOU Shu Rong GUO Chang Yi ZANG Jia Jie ZHU Zhen Ni MI Ming HUANG Cui Hua YU Hui Ting LU Xi RUAN Ye WU Fan | 2016 | Biomedical and Environmental Sciences2016，29，6： | 25 |
| 10 | Diagnosis and treatment of hepatic angiomyolipoma in 26 cases显示文摘AIM: To summarize the experience of the diagnosis and treatment of hepatic angiomyolipoma (HAML).METHODS: The clinical, imaging and pathological features,and treatment strategies of 26 patients with HAML treated at the authors′institute between October 1998 and January 2003 were retrospectively analyzed. All the patients received liver resection and were followed up till the study.Immunohistochemical assays were performed with a panel of antibodies.RESULTS: There was an obvious female predominance (21:5), and most of the patients (18/26) had no symptoms.Heterogeneous high echo was found in ultrasonography and punctiform or filiform vascular distribution pattern was found in color Doppler-sonography in most of the lesions (21/26).All of the 5 lesions further enhanced with Levovist showed early and prolonged enhancement. At contrast-enhanced spiral CT, the soft-tissue components of 24 lesions were markedly enhanced in the arterial phase and 18 lesions remained enhanced in the portal venous phase. MRI was performed in 9 patients, and showed hypointensity or hyperintensity on T1-weighted images and heterogeneous hyperintensity on T2-weighted images. Histopathologically,all lesions were composed of adipose tissues, smooth muscle and blood vessels with different proportions. Most lesions showed positive immunohistochemical staining for HMB45(26/26), A103 (24/26) and SMA (24/26). All of the 26 patients showed a benign course with no sign of recurrence.CONCLUSION: Preoperative radiological diagnosis of HAML is possible. The demonstration of intratumoral fat and central vessels is helpful in the diagnosis. HMB45, A103 and SMA are promising markers for pathologic diagnosis of HAML,and surgical resection is effective for the treatment of HAML. | Ning Ren Lun-Xiu Qin Zhao-You Tang Zhi-Quan Wu Jia Fan, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China | 2003 | World Journal of Gastroenterology2003，9，8： | 25 |
| 11 | Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction显示文摘背景:阿司匹林和 clopidogrel 能改进心肌的灌注并且在经皮的冠的干预(一种总线标准) 期间减轻心肌的损害。静脉内的 tirofiban 的增加是否在这个过程期间生产进一步的利益,没在圣片断举起被澄清心肌的梗塞(STEMI ) 病人。我们在经由 transradial 动脉途径经历了主要一种总线标准(p 一种总线标准) 的 STEMI 病人上评估了这。方法:连续病人被使随机化进 tirofiban 组(n=72 ) 或安慰剂组(n=78 ) 。起始的包括的 Angiographic 分析和在心肌的梗塞(TIMI ) 的最后的血栓溶解流动等级(TFG ) ,改正的 TIMI 框架计数(CTFC ) 和血栓形成容器的心肌的灌注分级的 TIMI (TMPG ) 。血小板聚集率(同等) ,肌酸磷酸激酶(CPK ) , CPK isoenzyme MB (CPK-MB ) 和我铺平的 troponin 被测量, TIMI 定义被用来估计流血复杂并发症。左室的表演参数与平衡放射性核种脑室造影术被调查。主要不利心脏的事件(向) 被跟随在上面为 6 个月。结果:TFG 0 的案例并且 1 在一种总线标准前, TFG 0 指南电线的十字路口什么时候首先是在一种总线标准以后的 TFG 3 的更少,和案例,比在安慰剂组的那些是在 tirofiban 组的更多。最后的 CTFC 是少数和发生不回流现象更低,也最后的 TFG 3 的百分比比在安慰剂组(所有 P<0.05 ) 的那些在 tirofiban 组是更高的。吝啬的山峰 CPK-MB 显著地更低,当时左室的性能参数在一种总线标准以后的 1 个星期更在安慰剂组比那些在 tirofiban 组被改进。同等显著地立即在 tirofiban 注入以后被减少。在 tirofiban 组的 6 月的向的发生在安慰剂组显然是比那低的。没有统计差别关于为复杂并发症放血在二个组之间被注意。结论:除了在有经由 transradial 动脉存取的 p 一种总线标准的 STEMI 病人的阿司匹林和 clopidogrel,静脉内的 tirofiban 注入能快速禁止血小板聚集,松开闭塞的血栓,改进心肌的灌注并且减少有容器存取的很少复杂并发症的向的发生并且流血。 | FU Xiang-hua HAO Qing-qing JIA Xin-wei FAN Wei-ze GU Xin-shun WU Wei-li HAO Guo-zhen LI Shi-qiang JIANG Yun-fa GENG Wei | 2008 | Chinese Medical Journal2008，，6： | 22 |
| 12 | Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome显示文摘背景发生不回流现象限制经皮的冠的干预(一种总线标准) 的临床的结果。这使随机化的控制研究被设计总共在 PCI.Methods 期间在心肌的灌注和心肌的 ischemic 损害上评估集中的 stalin 预告的处理的立即的保护的效果有急性冠的症候群(交流)的 228 个病人随机被分到标准 stalin 组( SS 组, n=115 )并且集中的 statin 组(组, n=113 )。在 SS 组的病人收到了 20 mg simvastatin,在 IS 组的病人在一种总线标准前收到了 80 mg simvastatin 7 天。在心肌的梗塞(TIMI ) 的 Thrombolysis 流动等级(TFG ) ,改正的 TIMI 框架计数(CTFC ) 和 TIMI 干涉容器的心肌的灌注等级(TMPG ) 在 stent 推广前后被记录。肌酸 kinase ( CK ) isoenzyme MB ,我和血浆高 sensitive-C 铺平的 troponin 反应蛋白质( hs-CRP ), P-selectin 和细胞间的粘附分子( ICAM )以前被测量并且在 procedure.Results 以后的 24 个小时在 stent 推广以后的 TFG 显著地与更少的 TIMI 0-1 和更多的 TIMI 3 血流动被改进在比在 SS 组是组(所有 P < 0.05 )。病人没有回流现象是更少在是组(P < 0.001 ) 。CTFC 比在 SS 组在 IS 组是更低的(P < 0.001 ) 。TMPG 也比在 SS 组(P=0.001 ) 在 IS 组被改进。尽管一种总线标准在过程以后在 CK-MB 24 小时引起了重要增加,提高的 CK-MB 价值是更低的在组比在 SS 组(18.74 吗?? | JIA Xin-wei FU Xiang-hua ZHANG Jing GU Xin-shun FAN Wei-ze WU Wei-li HAO Guo-zhen LI Shi-qiang JIANG Yun-fa | 2009 | Chinese Medical Journal2009，，6： | 22 |
| 13 | International consensus statement on robotic hepatectomy surgery in 2018显示文摘The robotic surgical system has been applied in liver surgery. However,controversies concerns exist regarding a variety of factors including the safety,feasibility, efficacy, and cost-effectiveness of robotic surgery. To promote the development of robotic hepatectomy, this study aimed to evaluate the current status of robotic hepatectomy and provide sixty experts' consensus and recommendations to promote its development. Based on the World Health Organization Handbook for Guideline Development, a Consensus Steering Group and a Consensus Development Group were established to determine the topics, prepare evidence-based documents, and generate recommendations. The GRADE Grid method and Delphi vote were used to formulate the recommendations. A total of 22 topics were prepared analyzed and widely discussed during the 4 meetings. Based on the published articles and expert panel opinion, 7 recommendations were generated by the GRADE method using an evidence-based method, which focused on the safety, feasibility, indication,techniques and cost-effectiveness of hepatectomy. Given that the current evidences were low to very low as evaluated by the GRADE method, further randomized-controlled trials are needed in the future to validate these recommendations. | Rong Liu Go Wakabayashi Hong-Jin Kim Gi-Hong Choi Anusak Yiengpruksawan Yuman Fong Jin He Ugo Boggi Roberto I Troisi Mikhail Efanov Daniel Azoulay Fabrizio Panaro Patrick Pessaux Xiao-Ying Wang Ji-Ye Zhu Shao-Geng Zhang Chuan-Dong Sun Zheng Wu Kai-Shan Tao Ke-Hu Yang Jia Fan Xiao-Ping Chen | 2019 | World Journal of Gastroenterology2019，25，12： | 23 |
| 14 | Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota显示文摘BACKGROUND We previously showed,using the Traditional Chinese Medicine System Pharmacology Database,that Gegen Qinlian decoction(GQD)had a direct antitumor effect,and was combined with programmed cell death protein(PD)-1 inhibitors to treat microsatellite stable(MSS)tumor-bearing mice.However,the effect of GQD on patients with colorectal cancer(CRC)is not clear.AIM To determine the therapeutic mechanism of GQD in improving immune function,reducing inflammation and protecting intestinal barrier function.METHODS Seventy patients with CRC were included in this study:37 in the control group and 33 in the treatment group.The proportions of CD4+T,CD8+T,natural killer(NK),NKT and T regulatory cells were measured by flow cytometry.Levels of the cytokines tumor necrosis factor(TNF)-α,interferon(IFN)-γ,interleukin(IL)-2,IL-6,IL-10 and serotonin(5-hydroxytryptamine;5-HT)in serum were assessed by enzyme-linked immunosorbent assay(ELISA).The expression of zonula occludens(ZO)-1,occludin,nuclear factor(NF)-κB and TNF-αin tumor and normal tissues was measured by immunohistochemistry.The composition of gut microbiota from patients in the treatment group was assessed using 16S rDNA analysis.RESULTS There were no adverse events in the treatment group.The proportion of CD4+T cells and NKT cells in the post-treatment group was significantly higher than that in the pre-treatment and control groups(P<0.05).The level of TNF-αin the posttreatment group was significantly lower than that in the pre-treatment and control groups(P<0.05).The concentration of 5-HT in the post-treatment group was significantly lower than that in the pre-treatment group(P<0.05).The expression of ZO-1 and occludin in tumor tissues in the treatment group was significantly higher than that in the control group(P<0.05).The expression of ZO-1 in normal tissues of the treatment group was significantly higher than that in the control group(P=0.010).Compared with the control group,expression of NF-κB and TNF-αin tumor tissues of the treatment group was significantly decreased(P<0.05).Compared with the pre-treatment group,GQD decreased the relative abundance of Megamonas and Veillonella.In addition,GQD increased the relative abundance of Bacteroides,Akkermansia and Prevotella.CONCLUSION GQD enhances immunity and protects intestinal barrier function in patients with CRC by regulating the composition of gut microbiota. | Yang Li Zhong-Xin Li Chen-Yang Xie Jing Fan Ji Lv Xin-Jian Xu Jian Lv Wen-Tao Kuai Yi-Tao Jia | 2020 | World Journal of Gastroenterology2020，26，48： | 23 |
| 15 | Robot-assisted one-stage resection of rectal cancer with liver and lung metastases显示文摘The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery.The authors of this article present a case of robot-assisted, one-stage radical resection of three tumors, including robotic anterior resection for rectal cancer, segmental hepatectomy for liver metastasis, and wedge-shaped excision for lung metastasis.A 59-year-old man with primary rectal cancer and liver and lung metastases was operated upon with a one-stage radical resection approach using the Da Vinci Surgical System.Resection and anastomosis of rectal cancer were performed extracorporeally afterundocking the robot.The procedure was successfully completed in 500 min.No surgical complications occurred during the intervention and postoperative period, and no conversion to laparotomy or additional trocars were required.To the best of our knowledge, this is the first case of simultaneous resection for rectal cancer with liver and lung metastases using the Da Vinci Surgery System to be reported.The procedure is feasible and safe and its main advantages for patient are avoiding repeated operation, reducing surgical trauma, shortening recovery time, and early implementation of postoperative adjuvant therapy. | Jian-Min Xu Ye Wei Xiao-Ying Wang Hong Fan Wen-Ju Chang Li Ren Wei Jiang Jia Fan Xin-Yu Qin | 2015 | World Journal of Gastroenterology2015，21，9： | 23 |
| 16 | Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing显示文摘Hepatocellular 癌(HCC ) 是癌症实质词法,基因并且 phenotypic 差异。然而,我们不理解在 intratumor 异质和肿瘤的联系词法 / 组织学的特征之间的关系。用介绍 96 个肿瘤房间(30-36 各个) 和 15 个正常的肝房间(5 各个) 的单个房间的整个染色体的定序,与联系 HBV 的 HCC 从三个男病人收集了,我们证实拷贝数字变化在 hepatocarcinogenesis 早发生,但是此后在整个肿瘤仍然保持相对稳定前进。重要地,我们证明特定的 HCC 能具有 monoclonal 或 polyclonal 起源。有汇合的 multinodular 形态学的肿瘤是典型 polyclonal 肿瘤并且显示最高的 intratumor 异质。除了 mutational 和拷贝数字侧面,我们把了用导出 HBV 的外国 genomic 标记的 HCC 的同种细胞的起源。在 monoclonal HCC,所有肿瘤单身者房间展出一样的 HBV 集成,显示 HBV 集成是一个早司机事件并且在肿瘤前进期间仍然保持极其稳定。另外,我们的结果显示那两个都转移,迟了的传播并且早播种当模特儿,在 HCC 有一个角色前进。尤其是,开始的克隆传播的早 intrahepatic 导致同步 multifocal 肿瘤的形成。同时,我们在 HCC 识别了潜在的司机基因 ZNF717,它展出变化的高频率在单个房间并且人口铺平,,通过调整 IL-6/STAT3 小径行动的肿瘤 suppressor。这些调查结果热点多重不同肿瘤在 HCC 的进化机制,它为特定的处理策略建议需要。 | Meng Duan, Shu Zhang, Zhichao Wang, Jieyi Shi, Longzi Liu, Xiaoying Wang, Aiwu Ke, Jian Zhou, Jia Fan, Qiang Gao Junfeng Hao, Chong Li Sijia Cui Daniel L Worthley Ya Cao Ruibin Xi Xiaoming Zhang Jian Zhou, Jia Fan Qiang Gao | 2018 | Cell Research2018，28，3： | 21 |
| 17 | Sutureless Intestinal Anastomosis with a Novel Device of Magnetic Compression Anastomosis显示文摘Objective To explore the feasibility and efficiency of a novel magnetic compression anastomats(MCAs) in intestinal anastomosis.Methods A total of 36 male mongrel canines underwent intestinal anastomosis using traditional hand-sewn(n=18) or a novel MCAs(n=18).We compared the anastomosis time,postoperative complications,bursting strength of anastomoses,gross appearance,and pathology between two groups at each time-point of follow-up.Results The mean anastomosis time with MCAs was significantly less than that with hand-sewn(8.50±1.95 vs.31.1±4.32 minutes,P<0.001).The blood stools and intussusceptions occurred in both groups during follow-up period.Only 1 mongrel canine receiving intestinal anastomosis by MCAs experienced anastomotic leakage.The average bursting pressure of anastomoses obtained from mongrel canines undergoing intestinal anastomosis by MCAs was significantly higher than that by traditional hand-sewn at 1 week's follow-up time(P<0.05).Gross appearance of the anastomoses constructed by MCAs was relatively smoother and flatter.Pathological evalution of anastomoses revealed that general inflammation was greater in hand-sewn anastomoses than magnetic anastomosis.Conclusion The magnetic compression anastomat is a safe and effective device of sutureless intestinal anastomosis in canine models. | Chao Fan Jia Ma Hong-ke Zhang Rui Gao Jian-hui Li Liang Yu Zheng Wu Yi Lv | 2011 | Chinese Medical Sciences Journal2011，26，3： | 20 |
| 18 | Therapeutic effect of Zijin capsule in liver fibrosis in rats显示文摘TherapeuticefectofZijincapsuleinliverfibrosisinratsCAIDaYongZHAOGang,CHENJiaChun,YEGanMei,BINGFeiHongandFANBuWuSubjecth... | CAI Da Yong, ZHAO Gang, CHEN Jia Chun, YE Gan Mei, BING Fei Hong and FAN Bu Wu | 1998 | World Journal of Gastroenterology1998，4，3： | 20 |
| 19 | Plant Prime Editors Enable Precise Gene Editing in Rice Cells显示文摘Genome editing is revolutionizing plant research and crop breeding.Sequence-specific nucleases(SSNs)such as zinc finger nuclease(ZFN)and TAL effector nuclease(TALEN)have been used to create site-specific DNA double-strand breaks and to achieve precise DNA modifications by promoting homology-directed repair(HDR)(Steinert et al.,2016;Voytas,2013).Later,RNA-guided SSNs such as CRISPR-Cas9,Cas12a,Cas12b,and their variants were applied for genome editing in plants(Li et al.,2013;Nekrasov et alM 2013;Tang et al.,2017;Zhong et al.,2019;Ming et al.,2020;Tang et al.,2019).However,HDR relies on simultaneous delivery of SSNs and DNA donors,which has been challenging in plants(Steinert et al.,2016;Zhang et aL,2019).Another challenge for realizing efficient HDR in plants is that DNA repair favors nonhomologous end joining(NHEJ)pathways over HDR in most cell types(Puchta,2005;Qi et al.,2013). | Xu Tang Simon Sretenovic Qiurong Ren Xinyu Jia Mengke Li Tingting Fan Desuo Yin Shuyue Xiang Yachong Guo Li Liu Xuelian Zheng Yiping Qi Yong Zhang | 2020 | Molecular Plant2020，13，5： | 20 |
| 20 | Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma:Report of an initial experience显示文摘瞄准:报导收到了 sirolimus 的 36 个病人的初步的结果的回顾的分析(SRL, Rapamune, rapamycin ) 在 248 肝的一个连续的队紧密相联的接枝接受者。方法:被换到的有肝细胞癌(HCC ) 的 36 个肝 transplant 病人从 tacrolimus 的基于 SRL 的免疫力的抑制治疗在这研究被注册。是在常位的肝移植( OLT )前推进了 HCC 被诊断的病人被划分成组 A ( n = 11 ),在 OLT 被分配组织 B 以后,被发现到的那些有 HCC 复发或转移( n = 18 ),并且 calcineurin 禁止者( CNI )引起的发达肾机能不全被分到谁的那些组织 C ( n = 7 )在 OLT 以后。结果:病人被跟随在上面为一 10.4 瞬间中部(范围, 3.8-19.1 瞬间) 在到 SRL 治疗和 12.3 瞬间的变换以后(范围, 5.1-34.4 瞬间) 在 OLT 以后。开发的三个病人在开始 SRL 治疗以后的 2 wk,它是充分在氢化尼松以后颠倒了的温和尖锐细胞的拒绝搏动治疗。在组 A,仅仅 1 个病人被发现有 HCC 复发和转移在 OLT 以后的 12 瞬间。在组 B, 66.7%(12/18 ) 病人们(2 与进步肿瘤, 7 与稳定的肿瘤并且 3 没有肿瘤) 由于在 6.8 瞬间柱子变换和 10.7 瞬间柱子 transplant 的中部的后续的结束为 HCC 复发交谈到 SRL 或切除术仍然是活着的。在组 C,没有 HCC 复发在 7 个病人被表明,并且肾的功能在 SRL 治疗以后变得正常。血小板减少(n = 2 ) ,贫血症(n = 8 ) ,并且口头的 aphthous (n = 7 ) 在我们的队发现是容易可管理的。结论:到基于 SRL 的免疫力的抑制的变换可以禁止 HCC 的复发和转移并且与 HCC 在 OLT 病人改进导致 CNI 的肾机能不全。 | Jian Zhou Jia Fan Zheng Wang Zhi-Quan Wu Shuang-Jian Qiu Xiao-Wu Huang Yao Yu Jian Sun Yong-Sheng Xiao Yi-Feng He Yu-Qi Wang Zhao-You Tang | 2006 | World Journal of Gastroenterology2006，12，19： | 20 |
您所在的机构暂未开通此部分的功能，请联系管理员